TTRXTurn Therapeutics Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $13.72 · now $13.72 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, TTRX has typically landed between $8.90 and $22.66 — a range of −35.1% to +65.1% from the issuance price $13.72.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

215 overlapping 1 month windows · 2025-10-082026-08-17 · basis climatology · forecast (batch).

The cone is anchored at the 2026-09-16 issuance close ($13.72) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where TTRX has typically landed a month from the 2026-09-16 close of $13.72 — the range is history, not a prediction.

$8.9worst · -35.1%$22.66best · +65.1%
  • now $13.72 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $14.71 (+7.2%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $11.63$17.78
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $8.9$22.66
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 215 windows spanning 2025-10-08 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2025-10-09−56.3%−56.3%+0.0%
2025-10-10−44.6%−46.0%+0.0%
2025-10-13−40.4%−40.4%+0.0%
3 best
2026-06-09+86.6%+0.0%+91.9%
2026-06-05+74.1%−4.2%+83.9%
2026-06-18+73.4%−1.7%+73.4%

215 overlapping windows · 2025-10-082026-09-16 · not cherry-picked

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$14$32025-12-12: 1 insider purchase, $9K — Chaudhary Zuraiz2025-11-24: 1 insider purchase, $34K — GOLDEN ARTHUR F2025-11-21: 2 insider purchases, $62K — GOLDEN ARTHUR F, Chaudhary Zuraiz2025-11-20: 1 insider purchase, $4K — Chaudhary Zuraiz2025-11-17: 1 insider purchase, $9K — Chaudhary Zuraiz2025-10-23: 3 insider purchases, $191K — GOLDEN ARTHUR F, Chesed Abraham, Chaudhary Zuraiz2025-10: 3 open-market purchases, $191K2025-11: 5 open-market purchases, $109K2025-12: 1 open-market purchase, $9K↑ buys↓ salesofficer Chaudhary Zuraiz — Purchase on 2025-12-12, filed same daydirector GOLDEN ARTHUR F — Purchase on 2025-11-24, filed 1 day after the tradedirector GOLDEN ARTHUR F — Purchase on 2025-11-21, filed 3 days after the tradeofficer Chaudhary Zuraiz — Purchase on 2025-11-21, filed same dayofficer Chaudhary Zuraiz — Purchase on 2025-11-20, filed 1 day after the tradeofficer Chaudhary Zuraiz — Purchase on 2025-11-17, filed same daydirector GOLDEN ARTHUR F — Purchase on 2025-10-23, filed same dayother Chesed Abraham — Purchase on 2025-10-23, filed 6 days after the tradeofficer Chaudhary Zuraiz — Purchase on 2025-10-23, filed same day
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2025-12-12Chaudhary ZuraizofficerPurchase2,500 @ $3.50$9K+25.0% of holding+37.4%+70.0%12,500Form 4 · filed same day
2025-11-24GOLDEN ARTHUR FdirectorPurchase9,868 @ $3.44$34K+19.5% of holding−18.7%+38.2%60,602Form 4 · filed 1 day after the trade
2025-11-21GOLDEN ARTHUR FdirectorPurchase20,532 @ $2.87$59K+68.0% of holding−13.0%+47.3%50,734Form 4 · filed 3 days after the trade
2025-11-21Chaudhary ZuraizofficerPurchase1,000 @ $3.29$3K+11.1% of holding−13.0%+47.3%10,000Form 4 · filed same day
2025-11-20Chaudhary ZuraizofficerPurchase1,450 @ $2.61$4K+19.2% of holding+6.2%+82.1%9,000Form 4 · filed 1 day after the trade
2025-11-17Chaudhary ZuraizofficerPurchase2,500 @ $3.62$9K+49.5% of holding−16.3%+24.0%7,550Form 4 · filed same day
2025-10-23GOLDEN ARTHUR FdirectorPurchase20,202 @ $4.95$100K+202.0% of holding−32.0%−32.3%30,202Form 4 · filed same day
2025-10-23Chesed AbrahamotherPurchase14,286 @ $4.60$66K+1.0% of holding−32.0%−32.3%1,447,268Form 4 · filed 6 days after the trade
2025-10-23Chaudhary ZuraizofficerPurchase5,050 @ $4.95$25Kownership Δ n/a−32.0%−32.3%5,050Form 4 · filed same day

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

17 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-04GOLDEN ARTHUR FdirectorAward / grant89,58489,584Form 4
2026-06-04Gengos AndrewdirectorAward / grant95,00095,000Form 4
2026-06-04Dewhurst Martin WilliamdirectorAward / grant71,66671,666Form 4
2026-06-04Kester Kent EdwarddirectorAward / grant83,33483,334Form 4
2026-05-28Burnam Bradley EvandirectorGift300,00015,116,260Form 4
2026-05-28Burnam Bradley EvandirectorGift300,00015,416,260Form 4
2026-05-28Burnam Bradley EvandirectorGift300,000300,000Form 4
2026-04-02GOLDEN ARTHUR FdirectorGift300,000360,602Form 4
2026-04-02Burnam Bradley EvandirectorGift300,00015,716,260Form 4
2026-04-01Burnam Bradley EvandirectorAward / grant160,000160,000Form 4
2026-04-01Chaudhary ZuraizofficerAward / grant80,00080,000Form 4
2026-01-07Dewhurst Martin WilliamdirectorAward / grant21,88221,882Form 4
2025-10-08Gengos AndrewdirectorAward / grant10,00010,000Form 4
2025-10-08Chaudhary ZuraizofficerAward / grant240,000240,000Form 4
2025-10-08Ghodadra Neilesh ShaileshdirectorAward / grant10,00010,000Form 4
2025-10-08Kester Kent EdwarddirectorAward / grant10,00010,000Form 4
2025-10-08GOLDEN ARTHUR FdirectorAward / grant10,00010,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.